Strengthening Egyptian Drug Authority’s regulatory functions – EG 23 NDICI HE 01 25

The "Strengthening Egyptian Drug Authority’s regulatory functions" project, designated as EG 23 NDICI HE 01 25, offers a grant opportunity under the EU’s Neighbourhood, Development and International Cooperation Instrument (NDICI). The total budget for this initiative is set at €1,500,000. This call specifically targets strengthening the regulatory framework of the Egyptian Drug Authority (EDA) to achieve the status of a WHO-listed Authority, thereby enhancing the regulation of medicinal products, vaccines, and medical devices in Egypt.

The opportunity is open for submissions, with a deadline of September 2, 2025. Eligible applicants must be public administrations from EU Member States, forming a consortium to collaborate with the EDA, which acts as the beneficiary institution within Egypt. The project falls into the health sector, notably focusing on pharmaceuticals and healthcare regulation.

Key documents related to this grant include the Twinning Fiche, which outlines the eligibility criteria and application details. The initiative ultimately aims to bolster the EDA's capabilities, contributing to public health improvements in Egypt while reinforcing EU-Egypt regulatory cooperation.

Strengthening Egyptian Drug Authority’s regulatory functions – EG 23 NDICI HE 01 25

This is an open call for submission of a grant.

General Information:

Documents:

Annex C9 Publication of Twinning Fiche, published 01 July 2025, in English.

Annex C1 Twinning Fiche, published 01 July 2025, in English.

The EU Funding & Tenders Portal manages this site via the Directorate-General for Research and Innovation.

Summary:

This is a call for action grant proposals focused on strengthening the regulatory functions of the Egyptian Drug Authority. The grant, with a budget of €1,500,000, falls under the Neighbourhood Programme and specifically targets Egypt. The call was published on July 1, 2025, and updated on June 22, 2025, with a submission deadline of September 2, 2025. Relevant documents, including the Twinning Fiche (Annex C1 and Annex C9), are available in English. Potential applicants should review these documents for detailed information on the objectives, eligibility criteria, and application process. The overall aim is to improve the Egyptian Drug Authority's capabilities through a twinning project.

Summary:

This opportunity is an Action Grant funded by the European Union under the Neighbourhood, Development and International Cooperation Instrument (NDICI). It aims to strengthen the regulatory functions of the Egyptian Drug Authority (EDA). The total budget for this action is €1,500,000. The call is open for submission, with a deadline of September 2, 2025. The program likely involves a "twinning" approach, where an organization or agency from an EU Member State partners with the EDA to provide expertise and support in enhancing its regulatory capabilities. Eligible applicants are likely to be government agencies or organizations capable of forming a twinning partnership. The project is focused on the development and implementation of regulatory improvements within the Egyptian pharmaceutical sector. The application process likely involves multiple stages. The specific details regarding application stages, success rates, and co-funding requirements would need to be confirmed by reviewing the official call documents, including the Twinning Fiche.